<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792996</url>
  </required_header>
  <id_info>
    <org_study_id>UNIVIE-BILIHEALTH</org_study_id>
    <nct_id>NCT04792996</nct_id>
  </id_info>
  <brief_title>Preventive Potential of Bilirubin</brief_title>
  <acronym>BILIHEALTH</acronym>
  <official_title>Investigating the Preventive Potential of Bilirubin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of mild hyperbilirubinemia, also known as Gilbert´s Syndrome, is usually&#xD;
      defined using an unconjugated bilirubin (UCB) blood concentration above 17.1 µmol/l. The&#xD;
      prevalence of GS is remarkably common, affecting 5-10% (depending on ethnicity and gender) of&#xD;
      the adult population.&#xD;
&#xD;
      The aim of this project is to investigate whether there is a difference in health related&#xD;
      marker between 60 subjects with Gilbert´s Syndrome (mild hyperbilirubinaemia) and 60 age and&#xD;
      gender matched control subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2014</start_date>
  <completion_date type="Actual">June 1, 2016</completion_date>
  <primary_completion_date type="Actual">June 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The investigators will consider Lipid parameter</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare plasma parameter of lipid metabolism (Cholesterol, LDL, HDL, Triglycerides, ..) between Gilbert´s Syndrome subjects and controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider plasma parameter of glucose metabolism</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare plasma parameter of glucose metabolism (plasma glucose (mg/dl), plasma insulin (µU/ml), C-peptide (ng/ml)) between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider AMPK metabolic pathway</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare parameter of the AMPK metabolic pathway (phosphorylated AMPK (rfU), phosphorylated Ppar-alpha (rfU), phosphorylated Ppar-gamma (rfU)) between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider body composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare parameter of the body composition (BMI (kg/m2), fat mass (%), waist circumference (cm), hip circumference (cm), abdominal circumference (cm)) between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider heme catabolic pathway</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare parameter of the heme catabolic pathway (expression of heme oxygenase (RQ), expression of Biliverdinreductase (RQ)) between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider the metabolomic response</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare the metabolomic pattern (ie all metabolites; analyzed using both nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques) between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider the composition of gut-microbiota</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare the composition of the gut microbiota (Gene sequencing of the 16S rRNA on the stool samples are performed to identify the microbes down to genus level as well as the microbial diversity and relative abundance) between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider oxidative stress marker</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare plasma concentrations of oxidative stress marker such as malondialdehyde or GSH/GSSG between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider anabolic and catabolic hormones</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare plasma concentrations of hormones (Glucagon (pg/ml), T3 (pg/ml), TSH(µM/ml),) between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider telomere length</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare telomere length between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider RNA and DNA gene expression</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare RNA and DNA gene expression between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The investigators will consider the metabolomic response after a standard breakfast</measure>
    <time_frame>Five blood samplings over 180 minutes.</time_frame>
    <description>Compare the metabolomic pattern after a standard breakfast (ie all metabolites; analyzed using both nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques) between Gilbert´s Syndrome subjects and controls.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Mild Hyperbilirubinaemia</condition>
  <arm_group>
    <arm_group_label>Gilbert´s Syndrome</arm_group_label>
    <description>Subjects with mild hyperbilirubinaemia and a plasma level of unconjugated bilirubin of 17.1 µmol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy controls with lower plasma level of unconjugated bilirubin of 17.1 µmol, aen and gender matched.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention. case - control design.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Gilbert´s Syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        120 participants, 60 participants with mild hyperbilirubinaemia, 60 subjects without mild&#xD;
        hyperbilirubinaemia, age and gender matching.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In general&#xD;
&#xD;
          -  Signed declaration of consent&#xD;
&#xD;
          -  Age: 20-80 years&#xD;
&#xD;
          -  Liver enzymes (AST, ALT, GGT) &lt; 1.5x over norm values&#xD;
&#xD;
          -  Non smoking&#xD;
&#xD;
          -  Moderate physical activity&#xD;
&#xD;
          -  Ability to communicate with the study team in the local language to understand the&#xD;
             study procedure&#xD;
&#xD;
        Cases (GS):&#xD;
&#xD;
          -  Total blood bilirubin &gt; 1.2 mg/dl&#xD;
&#xD;
          -  Unconjugated bilirubin &gt; 1 mg/dl&#xD;
&#xD;
        Controls (non-GS):&#xD;
&#xD;
          -  Total blood bilirubin ≤ 1.2 mg/dl&#xD;
&#xD;
          -  Unconjugated bilirubin ≤ 1 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In general&#xD;
&#xD;
          -  Age &lt; 20 or &gt; 80 years&#xD;
&#xD;
          -  Cardiovascular diseases&#xD;
&#xD;
          -  Liver diseases (including Hep B and C)&#xD;
&#xD;
          -  Cholelithiasis&#xD;
&#xD;
          -  Hemolysis&#xD;
&#xD;
          -  Renal diseases&#xD;
&#xD;
          -  Active tumors&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Professional athletes&#xD;
&#xD;
          -  Subjects with organ transplants&#xD;
&#xD;
          -  Intake of antioxidants within the last 4 weeks&#xD;
&#xD;
          -  Intake of liver influencing medication within the last 5 weeks&#xD;
&#xD;
        Cases (GS):&#xD;
&#xD;
          -  Total blood bilirubin ≤ 1.2 mg/dl&#xD;
&#xD;
          -  Unconjugated bilirubin ≤ 1 mg/dl&#xD;
&#xD;
        Controls (non-GS):&#xD;
&#xD;
          -  Total blood bilirubin &gt; 1.2 mg/dl&#xD;
&#xD;
          -  Unconjugated bilirubin &gt; 1 mg/dl&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vienna</investigator_affiliation>
    <investigator_full_name>Wagner Karl-Heinz</investigator_full_name>
    <investigator_title>Professor of Human Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

